Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
Hatem Soliman, Varsha Shah, Gordan Srkalović, et al.
BMC Cancer (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis
Otília Menyhárt, Balázs Győrffy
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 949-960
Open Access | Times Cited: 218
Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine
Stanisław Supplitt, Paweł Karpiński, Maria Sąsiadek, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1422-1422
Open Access | Times Cited: 103
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Sreyashi Das, Mohan Kumar Dey, Ram V. Devireddy, et al.
Sensors (2023) Vol. 24, Iss. 1, pp. 37-37
Open Access | Times Cited: 93
Biomarkers in Breast Cancer: An Old Story with a New End
Lyvia Neves Rebello Alves, Débora Dummer Meira, Luiza Poppe Merigueti, et al.
Genes (2023) Vol. 14, Iss. 7, pp. 1364-1364
Open Access | Times Cited: 50
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe
Simone Hettmer, Corinne M. Linardic, Anna Kelsey, et al.
European Journal of Cancer (2022) Vol. 172, pp. 367-386
Open Access | Times Cited: 41
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
Alejandro Ríos-Hoyo, Erin F. Cobain, Laura A. Huppert, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 22, pp. 2632-2636
Closed Access | Times Cited: 9
Precision medicine: Uses and challenges
Nardeep Naithani, Amar Tej Atal, TVSVGK Tilak, et al.
Medical Journal Armed Forces India (2021) Vol. 77, Iss. 3, pp. 258-265
Open Access | Times Cited: 41
Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
Katiane Tostes, Aléxia Polo Siqueira, Rui Manuel Reis, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 11887-11887
Open Access | Times Cited: 20
Omics Technologies Improving Breast Cancer Research and Diagnostics
Arianna Orsini, Chiara Diquigiovanni, Elena Bonora
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12690-12690
Open Access | Times Cited: 18
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)
Teresa Amaral, Tobias Sinnberg, Eftychia Chatziioannou, et al.
European Journal of Cancer (2022) Vol. 182, pp. 155-162
Closed Access | Times Cited: 23
Recent advancement in molecular tools for breast cancer diagnosis and therapy decision: Trends in future perspective
Riya Sharma, Priyanka Naithani, Pallavi Sharma, et al.
Elsevier eBooks (2025), pp. 113-130
Closed Access
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer
Veronica Jones, Hongwei Yin, Yuan Yuan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer
Jenny Fitzgerald, Debra F. Higgins, Claudia Mazo, et al.
Journal of Clinical Pathology (2021) Vol. 74, Iss. 7, pp. 429-434
Closed Access | Times Cited: 30
Evolution-Informed Strategies for Combating Drug Resistance in Cancer
Kristi Lin‐Rahardja, Davis T. Weaver, Jessica Scarborough, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6738-6738
Open Access | Times Cited: 12
Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial—a study protocol
Yasmin A. Civil, Arlene L. Oei, Katya M. Duvivier, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy
Konstantinos Venetis, Carlo Pescia, Giulia Cursano, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5717-5717
Open Access | Times Cited: 4
Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer
Helena Čelešnik, Uroš Potočnik
Cancers (2023) Vol. 15, Iss. 4, pp. 1087-1087
Open Access | Times Cited: 10
Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature
Jessica Scarborough, Steven A. Eschrich, Javier F. Torres–Roca, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 9
Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
Annelie Johansson, Nancy Yu, Adina Iftimi, et al.
International Journal of Cancer (2022) Vol. 150, Iss. 12, pp. 2072-2082
Open Access | Times Cited: 15
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
Luca Licata, Giulia Viale, Mario Giuliano, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
Romain Varnier, Christophe Sajous, Solène De Talhouet, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4840-4840
Open Access | Times Cited: 19
Real-world use of multigene signatures in early breast cancer: differences to clinical trials
Luca Licata, Rita De Sanctis, Andrea Vingiani, et al.
Breast Cancer Research and Treatment (2024) Vol. 205, Iss. 1, pp. 39-48
Open Access | Times Cited: 2
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study
Mary Kathryn Abel, Amy M. Shui, Michelle Melisko, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 17
Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer
Bárbara Costa, Nuno Vale
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3181-3181
Open Access | Times Cited: 11
Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers
Mark Uhlik, Daniel Pointing, Seema Iyer, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top